CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients: a PK Pilot Study
University of Minnesota
30 participants
Oct 2, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
Eligibility
Inclusion Criteria4
- Adult (18-70 year old) kidney transplant recipients
- Patients transitioning from conventional CNI-based immunosuppression to co-stimulatory blockade (belatacept) immunosuppression OR patients who are stable on belatacept immunosuppression at the time of initial CYTOGAM infusion
- CMV Ig Seronegative Recipient who received a CMV Ig seropositive Donor
- EBV IgG Positive
Exclusion Criteria5
- Pregnant people
- Subjects unwilling to sign consent and complete follow up visits
- Subjects with IgA immunodeficiency
- Subjects who are receiving IgG therapy or who have received IgG therapy within two months of study enrollment
- Patients who do not speak English and would need a translator and translated consent materials in order to obtain informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Cytogam is used for the prevention of cytomegalovirus (CMV) disease in kidney, lung, liver, pancreas, heart and bone marrow transplantation. We do not yet have data about how much cytogam reduces CMV in blood, or how quickly it reduces CMV in blood.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07096453